{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:06:21Z","timestamp":1760234781612,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Burkitt lymphoma\/leukemia (BL\/L) is an aggressive oncohematological disease. This study evaluated the population-based prognosis and survival on BL\/L as well as if BL\/L behaved as a risk factor for the development of second primary cancers (SPCs) and if other first tumors behaved as risk factors for the occurrence of BL\/L as an SPC. A retrospective cohort using the Surveillance, Epidemiology and End Results (SEER) Program (2008\u20132016) was performed. Kaplan\u2013Meier, time-dependent covariate Cox regression and Poisson regression models were conducted. Overall, 3094 patients were included (median, 45 years; IQR, 22\u201362). The estimated overall survival was 65.4 months (95% CI, 63.6\u201367.3). Significantly more deaths occurred for older patients, black race, disease at an advanced stage, patients without chemotherapy\/surgery and patients who underwent radiotherapy. Hodgkin lymphomas (nodal) (RR, 7.6 (3.9\u201315.0; p &lt; 0.001)), Kaposi sarcomas (34.0 (16.8\u201368.9; p &lt; 0.001)), liver tumors (3.4 (1.2\u20139.3; p = 0.020)) and trachea, mediastinum and other respiratory cancers (15.8 (2.2\u2013113.9; p = 0.006)) behaved as risk factors for the occurrence of BL\/L as an SPC. BL\/L was a risk factor for the occurrence of SPCs as acute myeloid leukemias (4.6 (2.1\u201310.4; p &lt; 0.001)), Hodgkin lymphomas (extranodal) (74.3 (10.0\u2013549.8; p &lt; 0.001)) and Kaposi sarcomas (35.1 (12.1\u2013101.4; p &lt; 0.001)). These results may assist the development of diagnostic and clinical recommendations for BL\/L.<\/jats:p>","DOI":"10.3390\/diseases9020043","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T21:24:29Z","timestamp":1623792269000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma\/Leukemia"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4081-117X","authenticated-orcid":false,"given":"Ana M.","family":"Della Rocca","sequence":"first","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana M.","family":"Fachi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre F.","family":"Cobre","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius L.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Let\u00edcia P.","family":"Leonart","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Steffenello-Durigon","sequence":"additional","affiliation":[{"name":"Hematology Service, University Hospital Professor Polydoro Ernani de S\u00e3o Thiago, Federal University of Santa Catarina, Florian\u00f3polis 88036-800, SC, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanita A. G.","family":"Del Moral","sequence":"additional","affiliation":[{"name":"Hematology Service, University Hospital Professor Polydoro Ernani de S\u00e3o Thiago, Federal University of Santa Catarina, Florian\u00f3polis 88036-800, SC, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-1703","authenticated-orcid":false,"given":"Luana","family":"Lenzi","sequence":"additional","affiliation":[{"name":"Department of Clinical Analyses, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[{"name":"Pharmaceutical Sciences Postgraduate Program, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"},{"name":"Department of Pharmacy, Federal University of Paran\u00e1, Curitiba 80210-170, PR, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_2","unstructured":"PathologyOutlines.com (2021, March 05). Lymphoma & Related Disorders-General-WHO Classification-B Cell. Available online: https:\/\/www.pathologyoutlines.com\/topic\/lymphomabcellwho.html."},{"key":"ref_3","unstructured":"Jaffe, E.S., Harris, N.L., Stein, H., and Vardiman, J.W. (2001). WHO Classification of Tumours-Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC). [3rd ed.]."},{"key":"ref_4","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J., and Vardiman, J.W. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, International Agency for Research on Cancer (IARC). [4th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/j.hoc.2016.07.009","article-title":"Update on Burkitt Lymphoma","volume":"30","author":"Dunleavy","year":"2016","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0140-6736(11)61177-X","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1365-2141.2008.07144.x","article-title":"Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin\u2019s lymphoma: Results of the FAB\/LMB 96 international study","volume":"141","author":"Gerrard","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1182\/blood-2014-06-538504","article-title":"How I treat Burkitt lymphoma in adults","volume":"124","author":"Jacobson","year":"2014","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(08)70139-6","article-title":"Treating Burkitt\u2019s lymphoma in Malawi, Cameroon, and Ghana","volume":"9","author":"Hesseling","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/pbc.25612","article-title":"Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma","volume":"62","author":"Depani","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nature Communications Editors (2018). Epidemiology is a science of high importance. Nat. Commun., 9, 1703.","DOI":"10.1038\/s41467-018-04243-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1002\/cncr.28264","article-title":"Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database","volume":"119","author":"Castillo","year":"2013","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1182\/blood-2012-12-475558","article-title":"Trends in survival of patients with Burkitt lymphoma\/leukemia in the USA: An analysis of 3691 cases","volume":"121","author":"Costa","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.3109\/10428194.2015.1007505","article-title":"Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma","volume":"56","author":"Rossi","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/annonc\/mdq697","article-title":"Risk for second malignancies in non-Hodgkin\u2019s lymphoma survivors: A meta-analysis","volume":"22","author":"Pirani","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: When genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2019, August 04). National Cancer Institute. Overview of the SEER Program, Available online: https:\/\/seer.cancer.gov\/about\/overview.html."},{"key":"ref_21","unstructured":"(2019, April 29). Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 18 Regs Custom Data (with Additional Treatment Fields), Nov 2018 Sub (1975\u20132016 Varying)-Linked To County Attributes-Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2019, Based on the November 2018 Submission. Available online: https:\/\/seer.cancer.gov\/seerstat\/."},{"key":"ref_22","unstructured":"(2019, November 15). Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence-SEER 18 Regs Custom Data (with Additional Treatment Fields), Nov 2018 Sub (2000\u20132016) <Katrina\/Rita Population Adjustment>-Linked to County Attributes-Total U.S., 1969\u20132017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Released April 2019, Based on the November 2018 Submission. Available online: https:\/\/seer.cancer.gov\/seerstat\/."},{"key":"ref_23","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2019, February 19). National Cancer Institute. SEER*Stat Software-Latest Release: Version 8.3.5-6 March 2018, Available online: https:\/\/seer.cancer.gov\/seerstat\/."},{"key":"ref_24","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2019, May 22). National Cancer Institute. Documentation for the ASCII Text Data Files., Available online: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2018\/TextData.FileDescription.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/sim.3623","article-title":"The estimation of average hazard ratios by weighted Cox regression","volume":"28","author":"Schemper","year":"2009","journal-title":"Stat. Med."},{"key":"ref_26","unstructured":"International Agency for Research on Cancer (IARC), World Health Organization (WHO), International Association of Cancer Registries (IACR), European Network of Cancer Registrier (ENCR) (2021, March 05). International Rules for Multiple Primary Cancers (ICD-O Third Edition). Internal Report No. 2004\/02., Available online: http:\/\/www.iacr.com.fr\/images\/doc\/MPrules_july2004.pdf."},{"key":"ref_27","unstructured":"National Cancer Institute (NCI) (2019, October 29). NIH. NCI Dictionary of Cancer Terms. Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bju.14841","article-title":"Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: A large-scale population-based analysis","volume":"124","author":"Mazzone","year":"2019","journal-title":"BJU Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.leukres.2016.06.005","article-title":"Therapy-related myelodysplastic syndrome following primary breast cancer","volume":"47","author":"Malmgren","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2019.05.004","article-title":"Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors","volume":"82","author":"Jamy","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/35041694","article-title":"The age of cancer","volume":"408","author":"DePinho","year":"2000","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13244-019-0733-7","article-title":"An update on Burkitt lymphoma: A review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence","volume":"10","author":"Kalisz","year":"2019","journal-title":"Insights Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1002\/cncr.23914","article-title":"Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma","volume":"113","author":"Wang","year":"2008","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cam4.1870","article-title":"Trends in survival of patients with stage I\/II Burkitt lymphoma in the United States: A SEER database analysis","volume":"8","author":"Liu","year":"2019","journal-title":"Cancer Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/jclinpath-2011-200118","article-title":"Sporadic Burkitt lymphoma in southern China: 12 years\u2019 experience in a single institution in Guangzhou","volume":"64","author":"Ye","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/ejh.12284","article-title":"Role of 18F-FDG-PET\/CT in the management of Burkitt lymphoma","volume":"94","author":"Capote","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1023\/A:1026321923883","article-title":"Race, socioeconomic status and stage at diagnosis for five common malignancies","volume":"14","author":"Schwartz","year":"2003","journal-title":"Cancer Causes Control"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1155\/2012\/480160","article-title":"Increasing incidence rates, distribution and histological characteristics of primary gastrointestinal non-Hodgkin lymphoma in a North American population","volume":"26","author":"Howell","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","article-title":"CNS prophylaxis in lymphoma: Who to target and what therapy to use","volume":"20","author":"Hill","year":"2006","journal-title":"Blood Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10552-008-9147-4","article-title":"Lymphoma survival patterns by WHO subtype in the United States, 1973-2003","volume":"19","author":"Han","year":"2008","journal-title":"Cancer Causes Control"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nrc1749","article-title":"Mechanisms of therapy-related carcinogenesis","volume":"5","author":"Allan","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jamaoncol.2017.2395","article-title":"Change in Pattern of Secondary Cancers After Kaposi Sarcoma in the Era of Antiretroviral Therapy","volume":"4","author":"Mukhtar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/QAI.0000000000001918","article-title":"Brief Report: Malignancies in Adults Living With HIV in Asia","volume":"80","author":"Jiamsakul","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s10147-019-01430-0","article-title":"Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: A SEER-based study","volume":"24","author":"Wei","year":"2019","journal-title":"Int. J. Clin. Oncol."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/2\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:14:23Z","timestamp":1760163263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/2\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["diseases9020043"],"URL":"https:\/\/doi.org\/10.3390\/diseases9020043","relation":{},"ISSN":["2079-9721"],"issn-type":[{"type":"electronic","value":"2079-9721"}],"subject":[],"published":{"date-parts":[[2021,6,15]]}}}